盐酸吡格列酮治疗2型糖尿病临床研究

目的 :评价盐酸吡格列酮治疗 2型糖尿病的疗效。方法 :将 2型糖尿病患者随机分为盐酸吡格列酮治疗组、优降糖对照组 ,观察治疗后两组患者空腹血糖 (FBG)、餐后 2h血糖 (PBG 2h、糖化血红蛋白 (HbAlC)、血浆胰岛素、C肽、2 4h尿白蛋白排泄量及血脂的变化 ,并按HOMA计算治疗前后抵抗指数 (IR)、胰岛素敏感指数 (ISI) ,比较其变化。结果 :盐酸吡格列酮明显降低 2型糖尿病患者的FBG、PBG、HbAlc,与对照组相似 ,但治疗组血浆胰岛素、C肽水平、2 4h尿蛋白排泄量下降 ,经计算IR、ISI ,显示胰岛素抵抗及敏感指数有明显改善 ,优于对照组。结论 :盐酸吡格列酮是一种新型有效的口服药物

The clinical research of Pioglitazone treating type Ⅱ diabeties

Objective:To evaluate the treating effect of Pioglitazone on type Ⅱ diabetes(DM).Methods:Patients with DM were divided randomly into two groups:the experimental group,treated with Pioglitazone.The control group,treated with glibenclamide.The fast blood glucose(FBG),past blood glucose two hours(PBG2 h),HbAlc,plasma insulin,C-peptide,24 hours quantitative of urinary protein and blood lipids level were observed in two groups before and after treating.Comparing the changes of them,according to HOMA,to calculation insulin resistant index(IR),insulin sensitive index(ISI)in two groups before and after treating.Results:It is similar to the control group,the experimental group,treated with Pioglitazone,can obviously reduce the FBG,PBG,HLAIC of the DM patients,but its plasma insulin,C-peptide level,24 hours quantitative of urinary protein,through calculation for IR,ISI.It is better than control group.Conclusion:Pioglitazone was a new type of effective oral reducing glucose medicine.